ArticleJournal of neuro-oncology2011
Age as an independent prognostic factor in patients with glioblastoma: a Radiation Therapy Oncology Group and American College of Surgeons National Cancer Data Base comparison.
Article in Journal of neuro-oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- An integrative survival analysis and a systematic review of the cerebellopontine angle glioblastomas.Scientific reports · 2023Pooled it
- Predictors of Survival in Patients Aged ≥70 with Glioblastoma: A Time-Dependent Multivariable Analysis.Cancers · 2026Article
- The Roles of AGTRAP, ALKBH3, DIVERSIN, NEDD8 and RRM1 in Glioblastoma Pathophysiology and Prognosis.Biomedicines · 2024Article
- Survival Outcome Prediction in Glioblastoma: Insights from MRI Radiomics.Current oncology (Toronto, Ont.) · 2024Article
- Article
- PLOD2 Is a Prognostic Marker in Glioblastoma That Modulates the Immune Microenvironment and Tumor Progression.International journal of molecular sciences · 2022Article
- Do elderly patients (≥ 75 years old) with glioblastoma benefit from more radical surgeries in the era of temozolomide?Neurosurgical review · 2022Article
- Impact of various prognostic factors on survival in glioblastoma: tertiary care institutional experience.Ecancermedicalscience · 2022Article
- Dynein Light Chain Protein Tctex1: A Novel Prognostic Marker and Molecular Mediator in Glioblastoma.Cancers · 2021Article
- Hemoglobin Levels and Red Blood Cells Distribution Width Highlights Glioblastoma Patients Subgroup With Improved Median Overall Survival.Frontiers in oncology · 2020Article
- Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.Journal of neuro-oncology · 2017Article
- Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy.Clinical Medicine Insights. Oncology · 2016Article
- Delineation of radiation therapy target volumes for patients with postoperative glioblastoma: a review.OncoTargets and therapy · 2016Review
- Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.Molecular cancer research : MCR · 2015Article
- Article
- Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era.Cancer medicine · 2014Article
- Isoform-level gene signature improves prognostic stratification and accurately classifies glioblastoma subtypes.Nucleic acids research · 2014Article
- Article
- Can the prognosis of individual patients with glioblastoma be predicted using an online calculator?Neuro-oncology · 2013Article
- Can irradiation of potential cancer stem-cell niche in the subventricular zone influence survival in patients with newly diagnosed glioblastoma?Journal of neuro-oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 12 institutions in 2 countries.
Funding
Abstract
Glioblastoma (GBM) is rare in early adulthood and little information is available on this subgroup. We investigated whether young age (18-30 years) had an independent effect on survival. We retrospectively reviewed patients from two large databases: Radiation Therapy Oncology Group (RTOG) and American College of Surgeons National Cancer Data Base (NCDB). In the RTOG evaluation, we analyzed all eligible GBM cases from 17 RTOG studies from 1974 to 2002. All patients with GBM during 1985-1998 in the NCDB were examined for comparison. Patients were divided into three cohorts: ages 18-30, 31-49, and ≥50. Overall survival, as a function of age (discreet and continuous), was assessed. The RTOG review included 3,136 patients: 112 (3.6%) were 18-30, 780 (24.9%) were 31-49, and 2,244 (71.6%) were ≥50. The median survival times of the three groups were 21.0, 13.5, and 9.1 months (P < 0.0001). Significant improvement in survival for younger patients was demonstrated with adjustment for recursive partitioning analysis (RPA) class. Of the 37,260 patients analyzed in the NCDB, 796 (2.1%) were 18-30, 5,711 (15.3%) were 31-49, and 30,753 (82.5%) were ≥50. The median survival times of the three groups were 18.0, 12.8, and 6.3 months (P < 0.0001). Data were not available for RPA class from this series. GBM is rare in young adulthood, comprising 2.1-3.6% of our patients. They have superior survival, even when adjusted for RPA class. More investigations on the unique biologic and clinical characteristics of tumors in this population are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.